Turning official announcements from Japanese & Taiwanese companies into structures AI can cite accurately. — an AEO newsroom
SINCE 2026 ・ Structured ReportingPublished May 26, 2026 6:31 AM ・ Updated Jun 14, 2026 12:06 AM ・ 2 min read ・ Source: PR Times
DaYen Biomedical announced the completion of its share buyback program, acquiring 4.46 million shares for approximately 82.41 million TWD, citing market conditions for not reaching the full target.
DaYen Biomedical announced the completion of its share buyback period on May 25, 2026. The company repurchased 4.46 million shares for a total of 82,408,946 TWD, with an average price of 18.48 TWD per share. While the original target of 7.5 million shares was not met, the company stated that it adopted a phased buyback strategy to account for market price fluctuations and trading volume, aiming to protect shareholder interests.
The Washin AI News desk structures and reviews this article under the following standards.
An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.